Trace determination of tamoxifen and 5-fluorouracil in hospital and urban wastewaters

被引:44
|
作者
Tauxe-Wuersch, A [1 ]
de Alencastro, LF [1 ]
Grandjean, D [1 ]
Tarradellas, J [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Lab Environm Chem & Ecotoxicol, CH-1015 Lausanne, Switzerland
关键词
tamoxifen; 5-fluorouracil; cytostatic; chemotherapy; cancer; pharmaceuticals; wastewaters; sewage-treatment plants;
D O I
10.1080/03067310500291502
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Tamoxifen and 5-fluorouracil are widely used in cancer therapy. They are highly toxic (teratogenic, mutagenic, etc.), as are most of the anticancer drugs. Two methods were set up to analyse these drugs in wastewaters to evaluate the potential for environmental contamination by cytostatic agents. Liquid-liquid extraction followed by purification on OASIS (R) MCX cartridge and gas chromatography with mass spectrometry detection (GC-MS) was used for the analysis of tamoxifen. 5-Fluorouracil was extracted with an ENV+(Isolute) cartridge (solid-phase extraction), derivatized with pentafluorobenzyl bromide (PFBBr) and detected by GC-MS. Both methods showed good recoveries (> 70%), repeatability (RSD < 10%) and limits of detection (LOD 6-15 ng/L). Wastewaters from a residential area, a hospital, and sewage-treatment plants (STPs) were analysed using the analytical methods developed in this study. Tamoxifen was detected in wastewaters of the hospital, residential area, and influent of STPs, but not in treated wastewaters. 5-Fluorouracil in all wastewaters was below the LOD of the analytical method.
引用
收藏
页码:473 / 485
页数:13
相关论文
共 50 条
  • [22] 5-Fluorouracil induced extravasation injury
    Reddy, Sangana Sunitha
    Somayaji, Shalaka
    Murthy, Mamatha Krishna
    Maka, Vinayak V.
    INDIAN JOURNAL OF CANCER, 2020, 57 (04) : 467 - 469
  • [23] Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
    Shiga, Taro
    Hiraide, Makoto
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (04)
  • [24] TRABECULECTOMY WITH 5-FLUOROURACIL
    WATANABE, J
    IWATA, K
    SAWAGUCHI, S
    NANBA, K
    ACTA OPHTHALMOLOGICA, 1991, 69 (04): : 455 - 461
  • [25] Resistance to 5-fluorouracil
    Mader, RM
    Müller, M
    Steger, GG
    GENERAL PHARMACOLOGY, 1998, 31 (05): : 661 - 666
  • [26] 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
    Boileve, Alice
    Wicker, Camille
    Verret, Benjamin
    Leroy, Florence
    Malka, David
    Jozwiake, Mathieu
    Pontoizeau, Clement
    Ottolenghi, Chris
    De Lonlay, Pascale
    Ducreux, Michel
    Hollebecque, Antoine
    ANTI-CANCER DRUGS, 2019, 30 (03) : 313 - 317
  • [27] Determination of 5-fluorocytosine, 5-fluorouracil, and 5-fluorouridine in hospital wastewater by liquid chromatography-mass spectrometry
    Skvara, Pavel
    Santana-Viera, Sergio
    Montesdeoca-Esponda, Sarah
    Mordacikova, Erika
    Santana-Rodriguez, Jose Juan
    Vojs Stanova, Andrea
    JOURNAL OF SEPARATION SCIENCE, 2020, 43 (15) : 3074 - 3082
  • [28] 5-Fluorouracil as a phosensitiser
    Pascu, ML
    Brezeanu, M
    Voicu, L
    Staicu, A
    Carstocea, B
    Pascu, RA
    IN VIVO, 2005, 19 (01): : 215 - 220
  • [29] 5-Fluorouracil associated neurovascular toxicities
    Ozer, Muhammet
    Dumas, Brett
    Horta, Lucas
    Sadrzadeh, Hossein
    CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
  • [30] Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer
    Eckel, F
    Lersch, C
    Lippl, F
    Assmann, G
    Schulte-Frohlinde, E
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2000, 19 (03) : 295 - 300